{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T11:59:36Z","timestamp":1795089576684,"version":"4.10.2"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T00:00:00Z","timestamp":1652400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073117"],"award-info":[{"award-number":["82073117"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173366"],"award-info":[{"award-number":["82173366"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Intrinsic and acquired anti-HER2 resistance remains a major hurdle for treating HER2-positive breast cancer. Using genome-wide CRISPR\/Cas9 screening in vitro and in vivo, we identify FGFR4 as an essential gene following anti-HER2 treatment. FGFR4 inhibition enhances susceptibility to anti-HER2 therapy in resistant breast cancer. Mechanistically, m6A-hypomethylation regulated FGFR4 phosphorylates GSK-3\u03b2 and activates \u03b2-catenin\/TCF4 signaling to drive anti-HER2 resistance. Notably, suppression of FGFR4 dramatically diminishes glutathione synthesis and Fe\n                    <jats:sup>2+<\/jats:sup>\n                    efflux efficiency via the \u03b2-catenin\/TCF4-SLC7A11\/FPN1 axis, resulting in excessive ROS production and labile iron pool accumulation. Ferroptosis, a unique iron-dependent form of oxidative cell death, is triggered after FGFR4 inhibition. Experiments involving patient-derived xenografts and organoids reveals a synergistic effect of anti-FGFR4 with anti-HER2 therapy in breast cancer with either intrinsic or acquired resistance. Together, these results pinpoint a mechanism of anti-HER2 resistance and provide a strategy for overcoming resistance via FGFR4 inhibition in recalcitrant HER2-positive breast cancer.\n                  <\/jats:p>","DOI":"10.1038\/s41467-022-30217-7","type":"journal-article","created":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T06:05:35Z","timestamp":1652421935000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":220,"title":["N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5205-9923","authenticated-orcid":false,"given":"Yutian","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoquan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9029-1574","authenticated-orcid":false,"given":"Feng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu-Mei","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2176-7684","authenticated-orcid":false,"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3145-5492","authenticated-orcid":false,"given":"Yanan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindong","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinpei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-097X","authenticated-orcid":false,"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3206-782X","authenticated-orcid":false,"given":"Hailin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0687-4238","authenticated-orcid":false,"given":"Xiaoming","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"30217_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"30217_CR2","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3322\/caac.21583","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis, C. E. et al. Breast cancer statistics, 2019. CA Cancer J. Clin. 69, 438\u2013451 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"30217_CR3","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1126\/science.2470152","volume":"244","author":"DJ Slamon","year":"1989","unstructured":"Slamon, D. J. et al. Studies of the HER-2\/neu proto-oncogene in human breast and ovarian cancer. Science 244, 707\u2013712 (1989).","journal-title":"Science"},{"key":"30217_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science 235, 177\u2013182 (1987).","journal-title":"Science"},{"key":"30217_CR5","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783\u2013792 (2001).","journal-title":"N. Engl. J. Med."},{"key":"30217_CR6","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond, E. H. et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673\u20131684 (2005).","journal-title":"N. Engl. J. Med."},{"key":"30217_CR7","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0140-6736(16)32616-2","volume":"389","author":"D Cameron","year":"2017","unstructured":"Cameron, D. et al. 11 years\u2019 follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389, 1195\u20131205 (2017).","journal-title":"Lancet"},{"key":"30217_CR8","doi-asserted-by":"publisher","first-page":"4265","DOI":"10.1200\/JCO.2005.04.173","volume":"23","author":"M Marty","year":"2005","unstructured":"Marty, M. et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 23, 4265\u20134274 (2005).","journal-title":"J. Clin. Oncol."},{"key":"30217_CR9","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1200\/JCO.20.01204","volume":"39","author":"M Piccart","year":"2021","unstructured":"Piccart, M. et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer in the APHINITY trial: 6 years\u2019 follow-up. J. Clin. Oncol. 39, 1448\u20131457 (2021).","journal-title":"J. Clin. Oncol."},{"key":"30217_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1056\/NEJMoa1914609","volume":"382","author":"RK Murthy","year":"2020","unstructured":"Murthy, R. K. et al. Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N. Engl. J. Med. 382, 597\u2013609 (2020).","journal-title":"N. Engl. J. Med."},{"key":"30217_CR11","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma, S. et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783\u20131791 (2012).","journal-title":"N. Engl. J. Med."},{"key":"30217_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/0008-5472.473.65.2","volume":"65","author":"P Nagy","year":"2005","unstructured":"Nagy, P. et al. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res. 65, 473\u2013482 (2005).","journal-title":"Cancer Res."},{"key":"30217_CR13","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/jnci\/djk134","volume":"99","author":"M Scaltriti","year":"2007","unstructured":"Scaltriti, M. et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J. Natl Cancer Inst. 99, 628\u2013638 (2007).","journal-title":"J. Natl Cancer Inst."},{"key":"30217_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1112-1","volume":"19","author":"L Zhang","year":"2020","unstructured":"Zhang, L. et al. The PI3K subunits, P110\u03b1 and P110\u03b2 are potential targets for overcoming P-gp and BCRP-mediated MDR in cancer. Mol. Cancer 19, 10 (2020).","journal-title":"Mol. Cancer"},{"key":"30217_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","volume":"6","author":"Y Nagata","year":"2004","unstructured":"Nagata, Y. et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6, 117\u2013127 (2004).","journal-title":"Cancer Cell"},{"key":"30217_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ccr.2007.08.030","volume":"12","author":"K Berns","year":"2007","unstructured":"Berns, K. et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12, 395\u2013402 (2007).","journal-title":"Cancer Cell"},{"key":"30217_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23052-9","volume":"12","author":"L Luo","year":"2021","unstructured":"Luo, L. et al. Disruption of FOXO3a-miRNA feedback inhibition of IGF2\/IGF-1R\/IRS1 signaling confers Herceptin resistance in HER2-positive breast cancer. Nat. Commun. 12, 2699 (2021).","journal-title":"Nat. Commun."},{"key":"30217_CR18","doi-asserted-by":"publisher","first-page":"11118","DOI":"10.1158\/0008-5472.CAN-04-3841","volume":"65","author":"R Nahta","year":"2005","unstructured":"Nahta, R., Yuan, L. X., Zhang, B., Kobayashi, R. & Esteva, F. J. Insulin-like growth factor-I receptor\/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res. 65, 11118\u201311128 (2005).","journal-title":"Cancer Res."},{"key":"30217_CR19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1001\/jamaoncol.2015.0830","volume":"1","author":"R Salgado","year":"2015","unstructured":"Salgado, R. et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol. 1, 448\u2013454 (2015).","journal-title":"JAMA Oncol."},{"key":"30217_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19494-2","volume":"11","author":"SA Hurvitz","year":"2020","unstructured":"Hurvitz, S. A. et al. Pathologic and molecular responses to neoadjuvant trastuzumab and\/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nat. Commun. 11, 5824 (2020).","journal-title":"Nat. Commun."},{"key":"30217_CR21","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu, S. Z. et al. A single-cell and spatially resolved atlas of human breast cancers. Nat. Genet 53, 1334\u20131347 (2021).","journal-title":"Nat. Genet"},{"key":"30217_CR22","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.cell.2020.02.019","volume":"180","author":"HY Chew","year":"2020","unstructured":"Chew, H. Y. et al. Endocytosis inhibition in humans to improve responses to ADCC-mediating antibodies. Cell 180, 895\u2013914.e27 (2020).","journal-title":"Cell"},{"key":"30217_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nrc.2017.8","volume":"17","author":"IS Babina","year":"2017","unstructured":"Babina, I. S. & Turner, N. C. Advances and challenges in targeting FGFR signalling in cancer. Nat. Rev. Cancer 17, 318\u2013332 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"30217_CR24","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","volume":"27","author":"JS Parker","year":"2009","unstructured":"Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160\u20131167 (2009).","journal-title":"J. Clin. Oncol."},{"key":"30217_CR25","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1158\/1078-0432.CCR-16-2287","volume":"23","author":"AB Hanker","year":"2017","unstructured":"Hanker, A. B. et al. HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2. Clin. Cancer Res. 23, 4323\u20134334 (2017).","journal-title":"Clin. Cancer Res."},{"key":"30217_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-020-00213-5","volume":"7","author":"SS Akhand","year":"2021","unstructured":"Akhand, S. S. et al. Fibroblast growth factor receptor facilitates recurrence of minimal residual disease following trastuzumab emtansine therapy. NPJ Breast Cancer 7, 5 (2021).","journal-title":"NPJ Breast Cancer"},{"key":"30217_CR27","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1158\/1078-0432.CCR-19-0353","volume":"26","author":"P Fern\u00e1ndez-Nogueira","year":"2020","unstructured":"Fern\u00e1ndez-Nogueira, P. et al. Tumor-associated fibroblasts promote HER2-targeted therapy resistance through FGFR2 activation. Clin. Cancer Res. 26, 1432\u20131448 (2020).","journal-title":"Clin. Cancer Res."},{"key":"30217_CR28","doi-asserted-by":"publisher","first-page":"6164","DOI":"10.1158\/1078-0432.CCR-16-0178","volume":"22","author":"G Piro","year":"2016","unstructured":"Piro, G. et al. An FGFR3 autocrine loop sustains acquired resistance to trastuzumab in gastric cancer patients. Clin. Cancer Res. 22, 6164\u20136175 (2016).","journal-title":"Clin. Cancer Res."},{"key":"30217_CR29","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/nm.2309","volume":"17","author":"S Zhang","year":"2011","unstructured":"Zhang, S. et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat. Med. 17, 461\u2013469 (2011).","journal-title":"Nat. Med."},{"key":"30217_CR30","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1158\/1541-7786.MCR-12-0155-T","volume":"10","author":"Y Wu","year":"2012","unstructured":"Wu, Y. et al. Expression of Wnt3 activates Wnt\/\u03b2-catenin pathway and promotes EMT-like phenotype in trastuzumab-resistant HER2-overexpressing breast cancer cells. Mol. Cancer Res. 10, 1597\u20131606 (2012).","journal-title":"Mol. Cancer Res."},{"key":"30217_CR31","doi-asserted-by":"publisher","first-page":"3761","DOI":"10.1073\/pnas.1014835108","volume":"108","author":"M Scaltriti","year":"2011","unstructured":"Scaltriti, M. et al. Cyclin E amplification\/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc. Natl Acad. Sci. USA 108, 3761\u20133766 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"30217_CR32","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.1158\/0008-5472.CAN-10-0545","volume":"70","author":"JR Carr","year":"2010","unstructured":"Carr, J. R., Park, H. J., Wang, Z., Kiefer, M. M. & Raychaudhuri, P. FoxM1 mediates resistance to herceptin and paclitaxel. Cancer Res. 70, 5054\u20135063 (2010).","journal-title":"Cancer Res."},{"key":"30217_CR33","doi-asserted-by":"publisher","first-page":"e48058","DOI":"10.15252\/embr.201948058","volume":"20","author":"HJ Choi","year":"2019","unstructured":"Choi, H. J. et al. CDK12 drives breast tumor initiation and trastuzumab resistance via WNT and IRS1-ErbB-PI3K signaling. EMBO Rep. 20, e48058 (2019).","journal-title":"EMBO Rep."},{"key":"30217_CR34","doi-asserted-by":"publisher","first-page":"5890","DOI":"10.1039\/C9CC02052G","volume":"55","author":"Z Zhou","year":"2019","unstructured":"Zhou, Z. et al. Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4. Chem. Commun. 55, 5890\u20135893 (2019).","journal-title":"Chem. Commun."},{"key":"30217_CR35","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1158\/1538-7445.AM2017-CT106","volume":"77","author":"SL Chan","year":"2017","unstructured":"Chan, S. L. et al. Ph I\/II study of FGF401 in adult pts with HCC or solid tumors characterized by FGFR4\/KLB expression [abstract]. Cancer Res. 77, 13 (2017).","journal-title":"Cancer Res."},{"key":"30217_CR36","doi-asserted-by":"publisher","first-page":"5685","DOI":"10.1200\/JCO.2008.21.4577","volume":"27","author":"H Joensuu","year":"2009","unstructured":"Joensuu, H. et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J. Clin. Oncol. 27, 5685\u20135692 (2009).","journal-title":"J. Clin. Oncol."},{"key":"30217_CR37","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1093\/annonc\/mdw262","volume":"27","author":"MV Dieci","year":"2016","unstructured":"Dieci, M. V. et al. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Ann. Oncol. 27, 1867\u20131873 (2016).","journal-title":"Ann. Oncol."},{"key":"30217_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1703643","volume":"377","author":"G von Minckwitz","year":"2017","unstructured":"von Minckwitz, G. et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N. Engl. J. Med. 377, 122\u2013131 (2017).","journal-title":"N. Engl. J. Med."},{"key":"30217_CR39","doi-asserted-by":"publisher","first-page":"e193692","DOI":"10.1001\/jamaoncol.2019.3692","volume":"6","author":"Z Shao","year":"2020","unstructured":"Shao, Z. et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: the PEONY phase 3 randomized clinical trial. JAMA Oncol. 6, e193692 (2020).","journal-title":"JAMA Oncol."},{"key":"30217_CR40","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain, S. M. et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 21, 519\u2013530 (2020).","journal-title":"Lancet Oncol."},{"key":"30217_CR41","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41392-020-00300-w","volume":"5","author":"H Song","year":"2020","unstructured":"Song, H. et al. Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduct. Target Ther. 5, 193 (2020).","journal-title":"Signal Transduct. Target Ther."},{"key":"30217_CR42","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13046-021-01952-4","volume":"40","author":"F Tan","year":"2021","unstructured":"Tan, F. et al. N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies. J. Exp. Clin. Cancer Res. 40, 146 (2021).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"30217_CR43","doi-asserted-by":"publisher","first-page":"5292","DOI":"10.1158\/1078-0432.CCR-17-3431","volume":"24","author":"M Tanioka","year":"2018","unstructured":"Tanioka, M. et al. Integrated analysis of RNA and DNA from the phase III Trial CALGB 40601 identifies predictors of response to trastuzumab-based neoadjuvant chemotherapy in HER2-positive breast cancer. Clin. Cancer Res. 24, 5292\u20135304 (2018).","journal-title":"Clin. Cancer Res."},{"key":"30217_CR44","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/onc.2016.338","volume":"36","author":"L Castagnoli","year":"2017","unstructured":"Castagnoli, L. et al. Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer. Oncogene 36, 1721\u20131732 (2017).","journal-title":"Oncogene"},{"key":"30217_CR45","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1200\/JCO.2009.25.4011","volume":"28","author":"RH Alvarez","year":"2010","unstructured":"Alvarez, R. H., Valero, V. & Hortobagyi, G. N. Emerging targeted therapies for breast cancer. J. Clin. Oncol. 28, 3366\u20133379 (2010).","journal-title":"J. Clin. Oncol."},{"key":"30217_CR46","doi-asserted-by":"publisher","first-page":"188","DOI":"10.2174\/1574892815666200910164641","volume":"15","author":"A Narayanankutty","year":"2020","unstructured":"Narayanankutty, A. Phytochemicals as PI3K\/ Akt\/ mTOR inhibitors and their role in breast cancer treatment. Recent Pat. Anticancer Drug Discov. 15, 188\u2013199 (2020).","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"30217_CR47","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon, S. J. et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060\u20131072 (2012).","journal-title":"Cell"},{"key":"30217_CR48","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/nature05859","volume":"447","author":"N Yagoda","year":"2007","unstructured":"Yagoda, N. et al. RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels. Nature 447, 864\u2013868 (2007).","journal-title":"Nature"},{"key":"30217_CR49","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1634\/theoncologist.2011-0165","volume":"16","author":"H Wong","year":"2011","unstructured":"Wong, H. et al. Integrating molecular mechanisms and clinical evidence in the management of trastuzumab resistant or refractory HER-2+ metastatic breast cancer. Oncologist 16, 1535\u20131546 (2011).","journal-title":"Oncologist"},{"key":"30217_CR50","doi-asserted-by":"publisher","first-page":"1900782","DOI":"10.1002\/advs.201900782","volume":"6","author":"K Huang","year":"2019","unstructured":"Huang, K. et al. Genome-wide CRISPR-Cas9 screening identifies NF-\u03baB\/E2F6 responsible for EGFRvIII-associated temozolomide resistance in glioblastoma. Adv. Sci. 6, 1900782 (2019).","journal-title":"Adv. Sci."},{"key":"30217_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13965-x","volume":"11","author":"B Li","year":"2020","unstructured":"Li, B. et al. Genome-wide CRISPR screen identifies host dependency factors for influenza A virus infection. Nat. Commun. 11, 164 (2020).","journal-title":"Nat. Commun."},{"key":"30217_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13420-x","volume":"10","author":"S Xu","year":"2019","unstructured":"Xu, S. et al. Genome-wide CRISPR screen identifies ELP5 as a determinant of gemcitabine sensitivity in gallbladder cancer. Nat. Commun. 10, 5492 (2019).","journal-title":"Nat. Commun."},{"key":"30217_CR53","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature13166","volume":"509","author":"Y Zhou","year":"2014","unstructured":"Zhou, Y. et al. High-throughput screening of a CRISPR\/Cas9 library for functional genomics in human cells. Nature 509, 487\u2013491 (2014).","journal-title":"Nature"},{"key":"30217_CR54","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/nrc.2016.140","volume":"17","author":"AT Byrne","year":"2017","unstructured":"Byrne, A. T. et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat. Rev. Cancer 17, 254\u2013268 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"30217_CR55","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1038\/s41568-018-0007-6","volume":"18","author":"J Drost","year":"2018","unstructured":"Drost, J. & Clevers, H. Organoids in cancer research. Nat. Rev. Cancer 18, 407\u2013418 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"30217_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19058-4","volume":"11","author":"B Schuster","year":"2020","unstructured":"Schuster, B. et al. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids. Nat. Commun. 11, 5271 (2020).","journal-title":"Nat. Commun."},{"key":"30217_CR57","doi-asserted-by":"publisher","first-page":"3744","DOI":"10.1016\/j.jmb.2014.09.004","volume":"426","author":"E Lesca","year":"2014","unstructured":"Lesca, E., Lammens, A., Huber, R. & Augustin, M. Structural analysis of the human fibroblast growth factor receptor 4 kinase. J. Mol. Biol. 426, 3744\u20133756 (2014).","journal-title":"J. Mol. Biol."},{"key":"30217_CR58","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1172\/JCI96708","volume":"128","author":"D Kogan","year":"2018","unstructured":"Kogan, D., Grabner, A., Yanucil, C., Faul, C. & Ulaganathan, V. K. STAT3-enhancing germline mutations contribute to tumor-extrinsic immune evasion. J. Clin. Investig. 128, 1867\u201372. (2018).","journal-title":"J. Clin. Investig."},{"key":"30217_CR59","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1038\/s41418-019-0321-x","volume":"26","author":"SP Turunen","year":"2019","unstructured":"Turunen, S. P. et al. FGFR4 phosphorylates MST1 to confer breast cancer cells resistance to MST1\/2-dependent apoptosis. Cell Death Differ. 26, 2577\u20132593 (2019).","journal-title":"Cell Death Differ."},{"key":"30217_CR60","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1172\/JCI130323","volume":"130","author":"S Garcia-Recio","year":"2020","unstructured":"Garcia-Recio, S. et al. FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease. J. Clin. Investig. 130, 4871\u20134887 (2020).","journal-title":"J. Clin. Investig."},{"key":"30217_CR61","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1177-1","volume":"21","author":"A Nagpal","year":"2019","unstructured":"Nagpal, A. et al. Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2(+ve) breast cancer metastasis. Breast Cancer Res. 21, 94 (2019).","journal-title":"Breast Cancer Res."},{"key":"30217_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.208","volume":"7","author":"S Ma","year":"2016","unstructured":"Ma, S., Henson, E. S., Chen, Y. & Gibson, S. B. Ferroptosis is induced following siramesine and lapatinib treatment of breast cancer cells. Cell Death Dis. 7, e2307 (2016).","journal-title":"Cell Death Dis."},{"key":"30217_CR63","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41568-019-0149-1","volume":"19","author":"JP Friedmann Angeli","year":"2019","unstructured":"Friedmann Angeli, J. P., Krysko, D. V. & Conrad, M. Ferroptosis at the crossroads of cancer-acquired drug resistance and immune evasion. Nat. Rev. Cancer 19, 405\u2013414 (2019).","journal-title":"Nat. Rev. Cancer"},{"key":"30217_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drup.2018.11.001","volume":"41","author":"Q Cui","year":"2018","unstructured":"Cui, Q. et al. Modulating ROS to overcome multidrug resistance in cancer. Drug Resist Update 41, 1\u201325 (2018).","journal-title":"Drug Resist Update"},{"key":"30217_CR65","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/hep.28574","volume":"64","author":"X Sun","year":"2016","unstructured":"Sun, X. et al. Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology 64, 488\u2013500 (2016).","journal-title":"Hepatology"},{"key":"30217_CR66","doi-asserted-by":"publisher","first-page":"101928","DOI":"10.1016\/j.redox.2021.101928","volume":"42","author":"T Hong","year":"2021","unstructured":"Hong, T. et al. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. Redox Biol. 42, 101928 (2021).","journal-title":"Redox Biol."},{"key":"30217_CR67","doi-asserted-by":"publisher","first-page":"101423","DOI":"10.1016\/j.redox.2019.101423","volume":"30","author":"S Bekeschus","year":"2020","unstructured":"Bekeschus, S. et al. xCT (SLC7A11) expression confers intrinsic resistance to physical plasma treatment in tumor cells. Redox Biol. 30, 101423 (2020).","journal-title":"Redox Biol."},{"key":"30217_CR68","doi-asserted-by":"publisher","first-page":"101297","DOI":"10.1016\/j.redox.2019.101297","volume":"26","author":"Z Li","year":"2019","unstructured":"Li, Z. et al. Carbonic anhydrase 9 confers resistance to ferroptosis\/apoptosis in malignant mesothelioma under hypoxia. Redox Biol. 26, 101297 (2019).","journal-title":"Redox Biol."},{"key":"30217_CR69","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/1574892813666180220110729","volume":"13","author":"SM Ferrari","year":"2018","unstructured":"Ferrari, S. M. et al. Lenvatinib in the therapy of aggressive thyroid cancer: state of the art and new perspectives with patents recently applied. Recent Pat. Anticancer Drug Discov. 13, 201\u2013208 (2018).","journal-title":"Recent Pat. Anticancer Drug Discov."},{"key":"30217_CR70","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1200\/JCO.2005.04.8587","volume":"24","author":"C Thussbas","year":"2006","unstructured":"Thussbas, C. et al. FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer. J. Clin. Oncol. 24, 3747\u20133755 (2006).","journal-title":"J. Clin. Oncol."},{"key":"30217_CR71","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","volume":"22","author":"T Helsten","year":"2016","unstructured":"Helsten, T. et al. The FGFR landscape in cancer: analysis of 4853 tumors by next-generation sequencing. Clin. Cancer Res. 22, 259\u2013267 (2016).","journal-title":"Clin. Cancer Res."},{"key":"30217_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-014-0554-4","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 554 (2014).","journal-title":"Genome Biol."},{"key":"30217_CR73","first-page":"1469","volume":"40","author":"Y Zou","year":"2019","unstructured":"Zou, Y. et al. circRAD18 sponges miR-208a\/3164 to promote triple-negative breast cancer progression through regulating IGF1 and FGF2 expression. Carcinogenesis 40, 1469\u20131479 (2019).","journal-title":"Carcinogenesis"},{"key":"30217_CR74","doi-asserted-by":"publisher","first-page":"2066","DOI":"10.1038\/s41418-019-0485-4","volume":"27","author":"L Yang","year":"2020","unstructured":"Yang, L. et al. Synergistic therapeutic effect of combined PDGFR and SGK1 inhibition in metastasis-initiating cells of breast cancer. Cell Death Differ. 27, 2066\u20132080 (2020).","journal-title":"Cell Death Differ."},{"key":"30217_CR75","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1038\/nmeth.3630","volume":"12","author":"PI Thakore","year":"2015","unstructured":"Thakore, P. I. et al. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat. Methods 12, 1143\u20131149 (2015).","journal-title":"Nat. Methods"},{"key":"30217_CR76","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1038\/s41587-020-0572-6","volume":"38","author":"C Wilson","year":"2020","unstructured":"Wilson, C., Chen, P. J., Miao, Z. & Liu, D. R. Programmable m(6)A modification of cellular RNAs with a Cas13-directed methyltransferase. Nat. Biotechnol. 38, 1431\u20131440 (2020).","journal-title":"Nat. Biotechnol."},{"key":"30217_CR77","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13045-020-00852-y","volume":"13","author":"S Zheng","year":"2020","unstructured":"Zheng, S. et al. Long non-coding RNA HUMT hypomethylation promotes lymphangiogenesis and metastasis via activating FOXK1 transcription in triple-negative breast cancer. J. Hematol. Oncol. 13, 17 (2020).","journal-title":"J. Hematol. Oncol."},{"key":"30217_CR78","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.cell.2017.11.010","volume":"172","author":"N Sachs","year":"2018","unstructured":"Sachs, N. et al. A living biobank of breast cancer organoids captures disease heterogeneity. Cell 172, 373\u2013386.e10 (2018).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30217-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30217-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30217-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T12:19:04Z","timestamp":1669292344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-30217-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,13]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["30217"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-30217-7","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,13]]},"assertion":[{"value":"19 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2672"}}